Baloxavir marboxil, Fremanezumab-vfrm, Galcanezumab-gnlm, and Lofexidine hydrochloride

J Am Pharm Assoc (2003). 2019 Jan-Feb;59(1):141-144. doi: 10.1016/j.japh.2018.12.002. Epub 2018 Dec 21.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / pharmacokinetics
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Clonidine / administration & dosage
  • Clonidine / adverse effects
  • Clonidine / analogs & derivatives*
  • Clonidine / pharmacokinetics
  • Clonidine / therapeutic use
  • Dibenzothiepins
  • Drug Interactions
  • Humans
  • Influenza, Human / drug therapy*
  • Migraine Disorders / drug therapy*
  • Morpholines
  • Oxazines* / administration & dosage
  • Oxazines* / adverse effects
  • Oxazines* / pharmacokinetics
  • Oxazines* / therapeutic use
  • Pyridines* / administration & dosage
  • Pyridines* / adverse effects
  • Pyridines* / pharmacokinetics
  • Pyridines* / therapeutic use
  • Pyridones
  • Substance Withdrawal Syndrome / drug therapy*
  • Thiepins* / administration & dosage
  • Thiepins* / adverse effects
  • Thiepins* / pharmacokinetics
  • Thiepins* / therapeutic use
  • Triazines* / administration & dosage
  • Triazines* / adverse effects
  • Triazines* / pharmacokinetics
  • Triazines* / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Dibenzothiepins
  • Morpholines
  • Oxazines
  • Pyridines
  • Pyridones
  • Thiepins
  • Triazines
  • baloxavir
  • erenumab
  • Clonidine
  • lofexidine